Last reviewed · How we verify
Triptans (triptans)
Triptans, marketed by Pfizer, are a leading family of antimigraine drugs primarily indicated for the acute treatment of migraine attacks with or without aura in adults. The key strength of triptans lies in their well-established efficacy and broad market acceptance, with a key composition patent expiring in 2028. However, the primary risk is the increasing competition from newer agents like Lasmiditan, Rimegepant, and Ubrogpant, which offer similar efficacy without the cardiovascular risks associated with triptans.
At a glance
| Generic name | triptans |
|---|---|
| Sponsor | Pfizer |
| Drug class | Selective serotonin receptor agonists |
| Target | Serotonin 5-HT1B/1D receptors |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Acute treatment of migraine attacks with or without aura in adults
- Cluster headache
Common side effects
Drug interactions
- Ergotamines
- Selective serotonin reuptake inhibitors (SSRIs)
- Monoamine oxidase inhibitors (MAOIs)
- CYP1A2 inhibitors (e.g., fluvoxamine)
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
- CYP2D6 inhibitors (e.g., paroxetine)
- Other triptans
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triptans CI brief — competitive landscape report
- Triptans updates RSS · CI watch RSS
- Pfizer portfolio CI